On the public citation graph

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD

https://doi.org/10.2147/copd.s159103
0 signed · 45 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/14651858.cd010115.pub2openalex-snapshot
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1007/s40258-016-0256-zopenalex-snapshot
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted…
inferredcites →https://doi.org/10.1007/s40273-012-0016-3openalex-snapshot
Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling
inferredcites →https://doi.org/10.1016/j.rmed.2009.09.007openalex-snapshot
Exploring the care needs of patients with advanced COPD: An overview of the literature
inferredcites →https://doi.org/10.1016/j.rmed.2014.09.015openalex-snapshot
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
inferredcites →https://doi.org/10.1016/s0140-6736(96)07492-2openalex-snapshot
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
inferredcites →https://doi.org/10.1016/s2213-2600(12)70052-8openalex-snapshot
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
inferredcites →https://doi.org/10.1016/s2213-2600(13)70052-3openalex-snapshot
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
inferredcites →https://doi.org/10.1056/nejmoa063070openalex-snapshot
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1093/oso/9780198526629.001.0001openalex-snapshot
Decision Modelling For Health Economic Evaluation
inferredcites →https://doi.org/10.1097/00008483-200007000-00015openalex-snapshot
Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1136/jech.41.4.355-aopenalex-snapshot
Methods for the economic evaluation of health care programmes
inferredcites →https://doi.org/10.1136/thorax.57.10.847openalex-snapshot
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1136/thorax.58.7.589openalex-snapshot
Time course of recovery of health status following an infective exacerbation of chronic bronchitis
inferredcites →https://doi.org/10.1136/thx.2005.040527openalex-snapshot
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1136/thx.51.3.277openalex-snapshot
Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population.
inferredcites →https://doi.org/10.1164/ajrccm.161.2.9901044openalex-snapshot
Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease: The Lung Health Study
inferredcites →https://doi.org/10.1164/rccm.2112055openalex-snapshot
Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1183/09031936.00200212openalex-snapshot
Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE study
inferredcites →https://doi.org/10.1183/09031936.01.00255301openalex-snapshot
Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag study
inferredcites →https://doi.org/10.1183/09031936.04.00055204openalex-snapshot
Prediction equations for normal and low lung function from the Health Survey for England
inferredcites →https://doi.org/10.1183/09031936.04.00120603openalex-snapshot
The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—
inferredcites →https://doi.org/10.1183/09031936.98.11061354openalex-snapshot
References values for forced spirometry. Group of the European Community Respiratory Health Survey
inferredcites →https://doi.org/10.1186/1471-2466-12-1openalex-snapshot
Up-to-date on mortality in COPD - report from the OLIN COPD study
inferredcites →https://doi.org/10.1186/1472-6963-6-52openalex-snapshot
Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation
inferredcites →https://doi.org/10.1371/journal.pone.0075221openalex-snapshot
Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study
inferredcites →https://doi.org/10.1378/chest.129.2.384openalex-snapshot
Updated Spirometric Reference Values for Adult Chinese in Hong Kong and Implications on Clinical Utilization
inferredcites →https://doi.org/10.1378/chest.130.4.1117openalex-snapshot
Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?
inferredcites →https://doi.org/10.2147/copdopenalex-snapshot
International Journal of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.2147/copd.s49615openalex-snapshot
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
inferredcites →https://doi.org/10.2147/copd.s56963openalex-snapshot
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
inferredcites →https://doi.org/10.2147/copd.s84436openalex-snapshot
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
inferredcites →https://doi.org/10.3109/15412555.2010.481697openalex-snapshot
The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3863358openalex-extracted
A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1016/j.chest.2018.06.021openalex-snapshot
Rebuttal From Drs Barrecheguren and Miravitlles
inferred← citeshttps://doi.org/10.1016/j.chest.2018.06.023openalex-snapshot
Rebuttal From Drs Cazzola and Matera
inferred← citeshttps://doi.org/10.1016/j.semerg.2021.08.001openalex-snapshot
Revisión narrativa de la terapia inhalatoria en la EPOC
inferred← citeshttps://doi.org/10.1016/j.semerg.2024.102284openalex-snapshot
Revisión narrativa de la terapia inhalatoria en la EPOC
inferred← citeshttps://doi.org/10.1080/13696998.2022.2043633openalex-snapshot
How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD
inferred← citeshttps://doi.org/10.1080/14656566.2021.1873953openalex-snapshot
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?
inferred← citeshttps://doi.org/10.1080/14737167.2020.1734456openalex-snapshot
Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2021-217962openalex-snapshot
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1186/s12890-021-01403-yopenalex-snapshot
A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.2147/copd.s247156openalex-snapshot
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
inferred← citeshttps://doi.org/10.6084/m9.figshare.13571903openalex-snapshot
Additional file 1 of A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.